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Immunotherapy in Allergic Asthma --
5  year analysis: Is it a curative
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Asthma  is  a  common,  chronic  and  heterogeneous  disease;
it  affects  people  of  all  ages  and  there  has  been  a  recent
increase  in  its  prevalence  and  severity.  It  may  be  mild,
barely  noticed  by  the  patient,  or  it  may  range  all  the  way  to
very  severe  disease,  causing  constant  symptoms  that  greatly
affect  the  quality  life  of  the  patient.  The  long-term  goals
of  asthma  management  are  to  achieve  good  symptom  con-
trol  and  minimize  future  risk  of  exacerbation,  fixed  air  flow
limitation  and  treatment  of  side  effects.1 The  patient  own
goals  regarding  their  asthma  and  its  treatment  should  also  be
identified.  During  the  last  decade  several  new  drugs  address-
ing  asthma  have  been  developed  and  approved.
The  immune  system  is  a  complex  interactive  network
with  the  capacity  of  protecting  the  host  from  a  number  of
pathogens  while  maintaining  a  state  of  tolerance  to  self
and  innocuous  exogenous  antigens.  Allergy  is  one  of  the
immune  tolerance-related  diseases  that  arises  as  a direct
consequence  of  a  dysregulated  immune  response.
Currently,  allergen-specific  immunotherapy  (allergen-
SIT)  remains  the  single  curative  approach  to  allergic  diseases
with  the  potential  to  modify  its  course.2 It  is  proven  to  be
the  only  therapy  that  alters  the  natural  history  of  allergic
disease,  prevents  progression,  prevents  the  development
of  new  sensitizations  and  may  even  prevent  the  develop-
ment  of  asthma  in  patients  with  allergic  rhinitis.3 It  consists
of  administering  gradually  increasing  doses  of  a  specific
allergenic  extract  to  an  allergic  subject  (with  specific  doc-
umented  IgE),  at  an  effective  dose,  in  order  to  decrease
the  symptoms  associated  with  subsequent  exposure  to  the
causative  allergen.3 Multiple  mechanisms  are  involved  in  the
suppression  and/or  control  of  allergic  inflammation.4 The
aim  of  allergen-SIT  is  to  induce  the  peripheral  T  cell  tol-
erance,  modulate  the  thresholds  for  mast  cell  and  basophil
activation  and  decrease  IgE-mediated  histamine  release.4
Peripheral  T  cell  tolerance  is  characterized  by  the  genera-
tion  of  allergen-specific  T-regulatory  cells  (Treg)  that  arePlease  cite  this  article  in  press  as:  Coutinho  Costa  J,  et  al.  Im
curative  approach?  Pulmonol.  2019.  https://doi.org/10.1016/j
able  to  produce  anti-inflammatory  cytokines  such  as  IL-
10  and  TGF-b.5 Treg  cells  not  only  diminish  Th2  immune
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BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)A  review  of  Abramson  et  al.,  which  included  eighty-eight
rials,  showed  a  significant  reduction  in  asthma  symp-
oms,  reduction  in  use  of  medications  and  improvement
n  bronchial  hyper-reactivity  following  immunotherapy.7
ccording  to  the  Global  Initiative  for  Asthma  (GINA)  2017,
or  patients  with  allergic  rhinitis  and  sensitization  to  house
ust  mite,  with  exacerbations  despite  low-high  dose  of  ICS,
e  must  consider  adding  sublingual  allergen  immunotherapy
SLIT),  provided  Fev1  is  >70%  predicted.1 Thus,  in  the  latest
INA  recommendations,  allergen-SIT  have  been  included  for
atients  with  exacerbation  despite  taking  step  3  or  step  4
herapy,  as  an  add-on  therapy.1
Here,  we  do  a  prospective  analysis  of  patients  with
sthma  submitted  to  allergen-SIT  followed  in  allergology
ppointment  during  5  years  (2013--2017).  Statistical  analysis
as  performed  using  the  IBM  SPSS
®
statistical  program,  ver-
ion  25.  The  variables  were  described  with  mean,  median,
tandard  deviation,  maximum  and  minimum.  All  the  tests
ere  considered  significant  when  p-value  did  not  exceed
.05.
We  included  35  patients  with  mean  age  28.1  ±  11.4
ears.  The  majority  (94.3%)  had  associated  allergic  rhini-
is.  Regarding  therapy  29%  of  the  patients  performed
llergen-SIT  for  dermatophagoides  pteronyssinus  (Dpt),
3%  Dpt/dermatophagoides  farinae,  14%  Dpt/Lepidoglyphus
estructor  and  31%  for  Gramineae  mixture.  The  majority  had
llergenic  polysensitization  (57%).
In  the  year  before  the  start  of  allergen-SIT,  patients  pre-
ented  an  average  of  3.9  ±  2.7  exacerbations/year  and  mean
ARAT  of  18  ±  2.3.  One  year  after  the  onset  of  allergen-SIT,
hey  presented  a  mean  of  0.14  ±  0.36  exacerbations/year
nd  mean  CARAT  of  22.8  ±  2.9.  At  3  years,  they  presented
 mean  of  0.05  ±  0.22  exacerbations/year  and  mean  CARAT
f  24.2  ±  2.7,  whereas  at  5  years,  they  presented  a  mean  of
.19  ±  0.40  exacerbations/year  and  mean  CARAT  of  23.8  ±  4.
uring  this  period  they  were  performing  therapy  on  step
 of  the  GINA.  There  were  statistically  significant  differ-
nces  in  the  number  of  exacerbations/year  and  the  CARAT
uestionnaire  mean  at  1,  3  and  5  years  (p  <  0.001).  There
ere  no  statistically  significant  differences  in  bronchodila-
or  and  anti-inflammatory  therapy  during  the  same  periodmunotherapy  in  Allergic  Asthma  --  5  year  analysis:  Is  it  a
.pulmoe.2019.01.007
p  =  0.282),  Table  1.  Regarding  safety,  most  local  adverse
eactions  were  mild  and  there  were  neither  life-threatening
ystemic  reactions  nor  fatal  events.





































































Year  before  the
beginning  of
SIT  (I)
1  year  after  the
start  of  SIT  (J)
3  years  after
the  start  of  SIT
(K)
5  years  after
the  start  of  SIT
(L)
pa 2 partial  Dif.  I-Jpb Dif.  I-Kpb Dif.  I-Lpb Dif.  J-Kpb Dif.  J-Lpb Dif.  K-Lpb
No.  exacerba-
tions/year
(Mean  ±  SD)
3.90  ±  2.72  0.14  ±  0.36  0.05  ±  0.22  0.19  ±  0.40  <0.001  0.670  <0.001  <0.001  <0.001  0.909  0.999  0.709
CARAT
(Mean ±  SD)






3  (1;  4)  3  (1;  4)  3  (1;  4)  3  (1;  4)  0.282  --  --  --  --  --  --  --
FEV1%
predicted
(Mean ±  SD)
97.3  ±  12.78  97.8  ±  8.43  102.6  ±  11.08  95.62  ±  11.22  0.295  0.078  1.000  0.434  1.000  0.654  0.987  0.474
PEF% predicted
(Mean  ±  SD)
84.5  ±  28.23  100.1  ±  21.80  95.3  ±  12.09  98.9  ±  13.40  0.101  0.128  0.564  0.361  0.332  1.000  1.000  1.000
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In  conclusion,  after  one  year  of  allergen-SIT,  we  verified
a  significant  symptomatic  improvement  in  the  clinical  con-
trol  of  asthma,  as  evidenced  by  the  statistically  significant
difference  in  the  number  of  exacerbations/year  and  in  the
CARAT  questionnaire.  This  control  remains  stable  after  3
and  5  years  of  therapy,  without  significant  differences  in
bronchodilator  and  anti-inflammatory  therapy.  Therefore,
the  current  evidence  provides  support  for  the  efficacy  and
safety  of  allergen-SIT  in  the  treatment  of  respiratory  allergy,
namely  in  clinical  control  of  allergic  asthma  and  rhinitis,
representing  a  safe  alternative  or  an  add-on  therapy  to  con-
ventional  inhaler  therapy.  However,  it  is  essential  to  select
patients  to  undergo  this  treatment  and  which  extracts  to  be
used  to  optimize  the  cost/benefit.
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